image

ASHCROFT PHARMACY

Register Online Pharmacy

MOUNJARO 2.5MG

Medication features Mounjaro is clinically proven weight loss aid prescribed to help with weight loss when others efforts have been ineffective. It works by acting on hormones responsible for blood sugar and appetite control. This reduces hunger and helps improve blood sugar levels. The once-weekly self-administering pen in user-friendly. This is supplied with enough needles for treatment

£105.00

£150.00

new
MOUNJARO 2.5MG

MOUNJARO 5MG

Mounjaro 5mg is one of the lower starting doses of tirzepatide, a once-weekly injectable medication primarily used for: • Type 2 diabetes management • Chronic weight management • Weight loss support: Even the 5mg dose can produce early weight loss in some patients.

£110.00

£160.00

new
MOUNJARO 5MG

MOUNJARO 7.5MG

Mounjaro 7.5mg is a moderate dose of tirzepatide, used after a patient tolerates lower doses (usually starting at 2.5mg → 5mg). It’s part of a stepped dosing schedule for improving blood sugar control and promoting weight loss. ⸻ 🔹 What to Know About Mounjaro 7.5mg • Frequency: Injected once weekly (same day each week) • Route: Subcutaneous (belly, thigh, or upper arm) • Progression: Typically prescribed after 4+ weeks on 5mg if well tolerated

£129.00

£180.00

new
MOUNJARO 7.5MG

MOUNJARO 10MG

Mounjaro 10mg is an advanced mid-to-high dose of tirzepatide, a weekly injectable medication approved for: • Type 2 diabetes management (under Mounjaro) • Chronic weight loss/obesity treatment It’s commonly used after patients build up from lower doses like 2.5mg, 5mg, and 7.5mg. ⸻ 🔹 Key Facts About Mounjaro 10mg • Dosage: Inject once weekly (same day/time each week) • Form: Prefilled auto-injector pen • Pack: Comes in a box of 4 pens (1 month supply)

£149.00

£200.00

new
MOUNJARO 10MG

MOUNJARO 12.5MG

Mounjaro 12.5mg is a higher dose of tirzepatide, typically used for people who have: • Progressed through lower doses (2.5 → 5 → 7.5 → 10mg) • Tolerated the medication well • Need stronger weight loss or blood sugar control It’s part of the standard step-up dosing schedule designed to reduce side effects while improving long-term effectiveness. 🔹 Quick Facts: Mounjaro 12.5mg Feature Info .🧴 Form Prefilled single-use auto-injector pen .📦 Box Contains 4 pens (1-month supply) .⏱️ Dosing Frequency Once weekly, same day/time each week .💉 Route Subcutaneous (thigh, abdomen, or arm)

£159.00

£210.00

new
MOUNJARO 12.5MG

MOUNJARO 15MG

Mounjaro 15mg is the highest approved dose of tirzepatide, used for: • Advanced type 2 diabetes treatment • Significant weight loss goals under medical supervision (also approved as Zepbound for weight loss) It’s typically reached after patients have safely progressed through lower doses like 2.5 → 5 → 7.5 → 10 → 12.5mg. 🔹 Key Details: Mounjaro 15mg Feature Description .🧴 Form Auto-injector pen (prefilled) .📦 Pack 4 pens per box (1 per week) .⏱️ Frequency Once weekly, same day/time .💉 Injection Site Belly, thigh, or upper arm

£179.00

£230.00

new
MOUNJARO 15MG

CAGRILINITIDE 5MG

Precision Weight Management. Unmatched Value for Researchers. 🔬 Product Overview Cagrilintide is a cutting-edge long-acting amylin analogue developed by Novo Nordisk This dual amylin and calcitonin receptor agonist offers a novel mechanism of action for weight management, providing researchers with a potent tool for metabolic health studies. 🚀 Key Benefits *Dual Receptor Activation: Simultaneously targets amylin and calcitonin receptors to regulate appetite, enhance satiety, and modulate glucose metabolism. *Clinically Proven Efficacy: Clinical studies have demonstrated that Cagrilintide leads to clinically significant, dose-dependent weight loss, with greater reductions observed at higher doses. *Enhanced Metabolic Health: Treatment with Cagrilintide has been associated with significant reductions in body weight and improved metabolic parameters. *Cost-Effective Research Tool: The 5mg vial offers a more affordable option for extended research protocols, reducing the cost per milligram compared to higher doss. 🧪 Composition *Active Ingredient: Cagrilintide *Concentration: 5mg per vial. *Form: Lyophilized peptide powder. 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period. 🛒 Order your 5mg Cagrilintide today for £200.00 (with free injection pen)

£140.00

£200.00

new
CAGRILINITIDE 5MG

CAGRILINITIDE 10MG

CAGRILINITIDE is a cutting-edge long-acting amylin analogue developed by Novo Norodisk. This dual amylin and calcitonin receptor agonist offers a novel mechanism of action for weight management, providing researchers with a potent tool for a metabolic health studies.

£200.00

£300.00

new
CAGRILINITIDE 10MG

RETATRUTIDE 30MG

Retatrutide 30mg is a next-generation injectable weight loss and diabetes drug currently in clinical development by Eli Lilly. It’s not yet approved by the FDA as of 2025, but it’s widely considered the most powerful obesity drug ever tested in clinical trials — even stronger than Mounjaro (tirzepatide). ⸻ 🔬 What Is Retatrutide? • Type: Triple hormone receptor agonist → Acts on GLP-1, GIP, and glucagon receptors • Dose: 30mg is the highest dose tested in clinical trials • Frequency: Once-weekly injection • Brand Name: Not yet announced (in development) ⸻ ⚙️ How Retatrutide Works It targets three metabolic pathways to: 1. Suppress appetite (like GLP-1s) 2. Enhance energy expenditure (via glucagon receptor) 3. Improve blood sugar control (via GIP and GLP-1) ⸻ 💥 Weight Loss Results (Clinical Trial Data) In a major Phase 2 trial, retatrutide 30mg led to: ✅ Average weight loss: 24.2% in 48 weeks ✅ Over 58 lbs lost (on average) for people starting around 240 lbs ✅ Results that exceeded tirzepatide (Mounjaro/Zepbound) These outcomes are unmatched by any currently approved medication.

£230.00

new
RETATRUTIDE 30MG

RETATRUTIDE 10MG Pen

Triple-Pathway Fat Loss. Maximum Metabolic Power. 🔬 Product Overview Retatrutide is a cutting-edge triple hormone receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. This multifaceted approach offers unparalleled potential in weight loss and metabolic health research. 🚀 Key Benefits Triple Hormone Activation: Engages GLP-1, GIP, and glucagon receptors to synergistically enhance weight loss and metabolic regulation. Superior Weight Reduction: In a 48-week phase 2 study, participants experienced up to 24.2% body weight loss with 12 mg dosing, surpassing results from other treatments like Ozempic and Mounjaro citeturn0search0. Enhanced Metabolic Health: Demonstrated improvements in liver fat content and cardiometabolic markers, indicating broader health benefits citeturn0search11. Reduced Dosing Frequency: Due to its potency, one vial will last for 5+weeks, depending on the research protocol. 🧪 Composition Active Ingredient: Retatrutide Concentration: 10mg per vial Form: Lyophilized peptide powder 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period. 🧠 Why Retatrutide Stands Out More Effective: Achieves greater weight loss in a shorter time frame compared to GLP-1 mono-agonists and dual agonists. Comprehensive Approach: Addresses multiple pathways involved in weight regulation and metabolic health. Research-Backed: Supported by robust clinical data demonstrating its efficacy and potential benefits citeturn0search0. 🔥 Pioneering the Future of Weight Loss Research Retatrutide represents a significant advancement in the field of metabolic research. Its unique triple-action mechanism offers a promising avenue for studies focused on obesity, type 2 diabetes, and related metabolic disorders.

£105.00

new
RETATRUTIDE 10MG Pen

RETATRUTIDE 20MG Pen

Active Ingredient: Retatrutide Concentration: 20mg per vial Form: Lyophilized peptide powder 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period.

£199.00

new
RETATRUTIDE 20MG Pen

SEMAGLUTIDE 10MG

Semaglutide is a GLP-1 receptor agonist available for research purposes only. It has shown significant potential in clinical studies for appetite suppression, weight loss, and blood sugar regulation. Available in 10mg, 20mg, and 30mg, this flexible dosing makes it an excellent option for researchers studying metabolic and weight loss treatments. Key Benefits: For research purposes only Effective for appetite suppression and metabolic regulation Flexible dosing options (10mg, 20mg, 30mg) Affordable and accessible for scientific studies (with free injection pen)

£139.99

£170.00

new
SEMAGLUTIDE 10MG

TIRZEPATIDE 10MG

Tirzepatide is a dual-action GLP-1 and GIP receptor agonist available for research purposes only. Its powerful combination of receptor activity has shown promising results in research for weight loss and metabolic health. Available in 10mg, 20mg, and 30mg, Tirzepatide offers an innovative approach for researchers exploring advanced metabolic and weight loss solutions. Key Benefits: For research purposes only Dual-action mechanism (GLP-1 and GIP) for enhanced metabolic effects Available in 10mg, 20mg, and 30mg doses for flexible research Ideal for advanced weight loss and metabolic health studies

£124.99

£150.00

new
TIRZEPATIDE 10MG

TIRZEPATIDE 20MG

🧪 Key difference: • The 20mg/mL vial is more concentrated, so you draw less liquid to get the same dose. • This matters when injecting with insulin syringes (measured in units).

£174.99

£210.00

new
TIRZEPATIDE 20MG

TIRZEPATIDE 30MG

30MG Tirzepatide is double dosage, double strength = double results. Higher dose means faster weight loss but not guaranteed benefits.

£269.99

new
TIRZEPATIDE 30MG